Workflow
Aidite(301580)
icon
Search documents
爱迪特(301580.SZ)发布上半年业绩,归母净利润9204.32万元,同比增长19.86%
智通财经网· 2025-08-25 10:15
智通财经APP讯,爱迪特(301580.SZ)发布2025年半年度报告,报告期内,公司实现营业收入4.86亿元, 同比增长17.22%。实现归属于上市公司股东的净利润9204.32万元,同比增长19.86%。实现归属于上市 公司股东的扣除非经常性损益的净利润8445.59万元,同比增长9.35%。基本每股收益0.86元。 ...
爱迪特(301580.SZ):上半年净利润9204.32万元 同比增长19.86%
Ge Long Hui A P P· 2025-08-25 08:59
格隆汇8月25日丨爱迪特(301580.SZ)公布2025年半年度报告,上半年公司实现营业收入4.86亿元,同比 增长17.22%;归属于上市公司股东的净利润9204.32万元,同比增长19.86%;归属于上市公司股东的扣 除非经常性损益的净利润8445.59万元,同比增长9.35%;基本每股收益0.86元。 ...
爱迪特(301580.SZ):拟2000万元设立爱迪特(杭州)数字科技
Ge Long Hui A P P· 2025-08-25 08:59
格隆汇8月25日丨爱迪特(301580.SZ)公布,根据公司业务发展规划及完善公司战略布局,公司拟使用自 有资金2,000万元对外投资设立全资子公司爱迪特(杭州)数字科技有限责任公司(暂定名,以市场监督管 理部门的最终登记为准),同时授权公司经营管理层在董事会批准的额度内根据项目开展情况决定资金 投入的方式及进度、办理相关手续等相关工作。 ...
爱迪特(301580) - 中信建投证券股份有限公司关于爱迪特(秦皇岛)科技股份有限公司增加2025年度日常关联交易预计额度的核查意见
2025-08-25 08:47
(一)日常关联交易概述 1、爱迪特(秦皇岛)科技股份有限公司于 2025 年 4 月 28 日召开第三届董事会 第十九次会议,审议通过了《关于 2025 年度日常关联交易预计的议案》,预计公司 及控股子公司 2025 年度与相关关联方可能发生的日常关联交易总金额为不超过人民 币 8,500.00 万元(不含税)。具体内容详见公司于 2025 年 4 月 29 日披露的《关于 2025 年度日常关联交易预计的公告》(公告编号:2025-002)。 2、公司根据《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》 等相关法律法规、规范性文件及《公司章程》有关规定,基于公司及子公司业务发 展及日常经营需要,公司预计增加与关联方景德镇万微新材料有限公司的日常关联 交易额度不超过 4,500.00 万元(不含税),交易类别为公司及子公司向景德镇万微新 材料有限公司采购原材料,以上额度自股东会审议通过之日起有效。 (二)预计新增日常关联交易类别和金额 结合公司业务发展需要,根据《深圳证券交易所创业板股票上市规则》等有关 规定,预计公司新增 2025 年度日常关联交易情况如下: | 关联 | 关联 | 关联 | 关 ...
爱迪特(301580) - 关于投资设立子公司的公告
2025-08-25 08:45
证券代码:301580 证券简称:爱迪特 公告编号:2025-042 爱迪特(秦皇岛)科技股份有限公司 关于投资设立子公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 4.注册地址:浙江省杭州市 5.经营范围:一般项目:技术服务、技术开发、技术咨询、技术交流、技术 转让、技术推广;软件开发;人工智能基础软件开发;人工智能应用软件开发; 信息系统集成服务;物联网技术服务;数据处理和存储支持服务;工业互联网数 据服务;医学研究和试验发展;教育咨询服务;第一类医疗器械销售;第二类医 疗器械销售;第三类医疗器械销售;计算机软硬件及辅助设备零售;技术进出口 (除依法须经批准的项目外,凭营业执照依法自主开展经营活动)。许可项目: 第二类医疗器械生产;第三类医疗器械生产;第二类医疗器械经营;第三类医疗 器械经营;医疗器械互联网信息服务;第二类增值电信服务。(依法须经批准的 项目,经相关部门批准后方可开展经营活动,具体经营项目以审批结果为准)。 6.出资方式:公司拟以自有资金出资,出资比例 100% 上述信息均以工商行政管理部门最终核准为准。 一、投资概述 爱迪特( ...
爱迪特(301580) - 2025年半年度募集资金存放与使用情况的专项报告
2025-08-25 08:45
证券代码:301580 证券简称:爱迪特 公告编号:2025-040 爱迪特(秦皇岛)科技股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 根据深圳证券交易所《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》及《深圳证券交易所创业板上市公司自律监管指南 第 2 号——公告格式》的规定,将爱迪特(秦皇岛)科技股份有限公司(以下 简称"公司")2025 年半年度募集资金存放与使用情况报告如下: 一、募集资金基本情况 (一)实际募集资金金额、资金到位时间 经中国证券监督管理委员会证监许可〔2023〕2615 号文核准,公司于 2024 年 6 月向社会公开发行人民币普通股(A 股)1,902.9382 万股,每股发行价为 44.95 元,应募集资金总额为人民币 85,537.07 万元,根据有关规定扣除发行费 用 9,405.50 万元后,实际募集资金金额为 76,131.57 万元。该募集资金已于 2024 年 6 月到账。上述资金到账情况业经容诚会计师事务所(特殊普通合伙) ...
爱迪特(301580) - 关于增加2025年度日常关联交易预计额度的公告
2025-08-25 08:45
爱迪特(秦皇岛)科技股份有限公司 证券代码:301580 证券简称:爱迪特 公告编号:2025-041 关于增加 2025 年度日常关联交易预计额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 爱迪特(秦皇岛)科技股份有限公司(下称"公司")于 2025 年 8 月 25 日召开第三届董事会第二十二次会议,审议通过了《关于增加 2025 年度日常关 联交易预计额度的议案》。现将有关情况公告如下: 一、日常关联交易基本情况 (一)日常关联交易概述 1.爱迪特(秦皇岛)科技股份有限公司(以下简称"公司")于 2025 年 4 月 28 日召开第三届董事会第十九次会议,审议通过了《关于 2025 年度日常关联 交易预计的议案》,预计公司及控股子公司 2025 年度与相关关联方可能发生的 日常关联交易总金额为不超过人民币 8,500.00 万元(不含税)。具体内容详见公 司于 2025 年 4 月 29 日披露的《关于 2025 年度日常关联交易预计的公告》(公 告编号:2025-002)。 2.公司根据《中华人民共和国公司法》《深圳证券交易所创业板股票上市 ...
爱迪特(301580) - 2025年半年度非经营性资金占用及其他关联资金往来情况汇总表
2025-08-25 08:45
爱迪特(秦皇岛)科技股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 注:总计数与各分项比例合计存在尾差,为四舍五入所致。 法定代表人:李洪文 主管会计工作负责人:孔祥乾 会计机构负责人:孔祥乾 编制:爱迪特(秦皇岛)科技股份有限公司 单位:万元 非经营性资金占用 资金占用方名称 占用方与上 市公司的关 联关系 上市公司核 算的会计科 目 2025 年期初 占用资金余额 2025 半年度占用 累计发生金额(不 含利息) 2025 半年度占 用资金的利息 (如有) 2025 半年度偿 还累计发生金 额 2025 半年度期 末占用资金余 额 占用形成 原因 占用性质 控股股东、实际控制人及 其附属企业 小计 — — — - - - - - 前控股股东、实际控制人 及其附属企业 小计 — — — - - - - - 其他关联方及其附属企 业 小计 — — — - - - - - 总计 — — — - - - - - 其他关联资金往来 资金往来方名称 往来方与上 市公司的关 联关系 上市公司核算 的会计科目 2025年初往来 资金余额 2025 半年度往来 累计发生金额(不 含利息) 20 ...
爱迪特(301580) - 关于召开2025年第三次临时股东会的通知
2025-08-25 08:45
证券代码:301580 证券简称:爱迪特 公告编号:2025-043 爱迪特(秦皇岛)科技股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 爱迪特(秦皇岛)科技股份有限公司(以下简称"公司")定于 2025 年 9 月 16 日(星期二)召开 2025 年第三次临时股东会,本次会议采取现场表决与网 络投票相结合的方式召开,现将有关事项通知如下: 一、召开会议的基本情况 (一)会议届次:2025 年第三次临时股东会 (二)会议召集人:董事会。公司于 2025 年 8 月 25 日召开了第三届董事会 第二十二次会议,审议通过了召开本次股东会的议案。 (三)会议召开的合法、合规性:本次股东会会议的召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的有关规定。 (四)会议召开的日期、时间: 1.现场会议:2025 年 9 月 16 日(星期二)14:30 2.网络投票:通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 9 月 16 日的交易时间,即 9:15-9:25,9:30-1 ...
爱迪特(301580) - 2025 Q2 - 季度财报
2025-08-25 08:45
Important Notes, Table of Contents, and Definitions [Important Notes](index=3&type=section&id=Important%20Notes) The board, senior management, and chief accountant affirm the report's truthfulness, accuracy, and completeness, while cautioning investors about risks and stating no interim dividend or capital increase plans - The company's board of directors, senior management, and chief accountant guarantee the report's truthfulness, accuracy, and completeness, advising investors to be aware of investment risks[6](index=6&type=chunk) - The company plans no interim cash dividends, bonus shares, or capital increase from capital reserves[7](index=7&type=chunk) [Table of Contents](index=4&type=section&id=Table%20of%20Contents) This section lists the report's eight main chapters, including company profile, management discussion and analysis, corporate governance, significant matters, share changes, bond information, and financial reports, with their respective starting page numbers [List of Reference Documents](index=5&type=section&id=List%20of%20Reference%20Documents) This section lists reference documents for the reporting period, including signed financial reports, original copies of all publicly disclosed company documents, and the legal representative's signed semi-annual report, available at the company's board office - Reference documents include signed and sealed financial reports, original copies of publicly disclosed documents, and the legal representative's signed report text[11](index=11&type=chunk)[12](index=12&type=chunk)[13](index=13&type=chunk) [Definitions](index=6&type=section&id=Definitions) This section defines common terms used in the report, covering company names, major shareholders, subsidiaries, product types (e.g., zirconia, glass ceramics, resin, dentures), and industry technologies (e.g., CAD, CAM), ensuring clear understanding of the report's content - The report defines the names of the company and its subsidiaries, such as Aidite, Tianjin Yuanyi, and Corigee[15](index=15&type=chunk) - It explains key products and materials, such as zirconia, glass ceramics, resin, and dentures (removable, fixed, implant-supported)[15](index=15&type=chunk)[16](index=16&type=chunk) - It covers dental medical technology terms, such as CAD (Computer-Aided Design) and CAM (Computer-Aided Manufacturing)[16](index=16&type=chunk) Company Profile and Key Financial Indicators [Company Profile](index=8&type=section&id=I.%20Company%20Profile) This section introduces the company's basic information, including its stock ticker "Aidite", stock code "301580", listing exchange (Shenzhen Stock Exchange), full Chinese name, abbreviation, foreign name, and legal representative Li Hongwen Company Basic Information | Indicator | Content | | :--- | :--- | | Stock Abbreviation | Aidite | | Stock Code | 301580 | | Listing Stock Exchange | Shenzhen Stock Exchange | | Chinese Name | Aidite (Qinhuangdao) Technology Co., Ltd. | | Legal Representative | Li Hongwen | [Contact Persons and Information](index=8&type=section&id=II.%20Contact%20Persons%20and%20Information) This section provides contact details for the company's Board Secretary Gao Yu and Securities Affairs Representative Zhu Menghan, including address, phone, fax, and email, for investor communication Company Contact Information | Position | Name | Contact Address | Phone | Fax | Email | | :--- | :--- | :--- | :--- | :--- | :--- | | Board Secretary | Gao Yu | No. 9 Dushan Road, Economic and Technological Development Zone, Qinhuangdao City, Hebei Province | 0335-8901545 | 0335-8691180 | investor@aidite.com | | Securities Affairs Representative | Zhu Menghan | No. 9 Dushan Road, Economic and Technological Development Zone, Qinhuangdao City, Hebei Province | 0335-8691180 | 0335-8691180 | investor@aidite.com | [Other Information](index=8&type=section&id=III.%20Other%20Information) During the reporting period, the company's contact information, information disclosure, and registration status remained unchanged, with a significant capital increase in June 2025 due to a 10-for-4 share transfer from capital reserves, raising total share capital from 76.12 million to 106.56 million shares - The company's registered address, office address, website, email, information disclosure and reference locations, and registration status remained unchanged during the reporting period[20](index=20&type=chunk)[21](index=21&type=chunk)[22](index=22&type=chunk) - In June 2025, the company completed its 2024 annual equity distribution, transferring **4 shares for every 10 shares** from capital reserves to all shareholders, increasing the total share capital from **76,117,527 shares to 106,564,537 shares**[23](index=23&type=chunk) - The company's registered capital changed from **76.12 million RMB to 106.56 million RMB**[23](index=23&type=chunk) [Key Accounting Data and Financial Indicators](index=9&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) This reporting period saw a 17.22% increase in operating revenue, a 19.86% rise in net profit attributable to shareholders, and a significant 141.72% surge in net operating cash flow, alongside growth in total assets and net assets, though basic and diluted EPS and ROE slightly decreased Key Accounting Data and Financial Indicators (Current Period vs. Prior Year) | Indicator | Current Period (RMB) | Prior Year (RMB) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 485,801,461.65 | 414,434,257.54 | 17.22% | | Net Profit Attributable to Shareholders of Listed Company | 92,043,207.47 | 76,789,371.20 | 19.86% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Items) | 84,455,933.14 | 77,237,194.04 | 9.35% | | Net Cash Flow from Operating Activities | 79,153,449.17 | 32,745,614.35 | 141.72% | | Basic Earnings Per Share (RMB/share) | 0.86 | 0.88 | -2.27% | | Diluted Earnings Per Share (RMB/share) | 0.86 | 0.88 | -2.27% | | Weighted Average Return on Net Assets | 4.54% | 6.90% | -2.36% | Key Accounting Data and Financial Indicators (End of Current Period vs. End of Prior Year) | Indicator | End of Current Period (RMB) | End of Prior Year (RMB) | Change from End of Prior Year | | :--- | :--- | :--- | :--- | | Total Assets | 2,370,561,012.21 | 2,287,843,452.73 | 3.62% | | Net Assets Attributable to Shareholders of Listed Company | 2,034,742,601.66 | 1,988,525,265.46 | 2.32% | [Differences in Accounting Data Under Domestic and Overseas Accounting Standards](index=9&type=section&id=V.%20Differences%20in%20Accounting%20Data%20Under%20Domestic%20and%20Overseas%20Accounting%20Standards) The company reported no differences in net profit and net assets between financial statements prepared under international or overseas accounting standards and those prepared under Chinese accounting standards during the reporting period - The company reported no differences in net profit and net assets under domestic and overseas accounting standards during the reporting period[25](index=25&type=chunk)[26](index=26&type=chunk) [Non-Recurring Gains and Losses and Amounts](index=9&type=section&id=VI.%20Non-Recurring%20Gains%20and%20Losses%20and%20Amounts) Non-recurring gains and losses totaled **7.59 million RMB** for the period, primarily from disposal of non-current assets, government grants, fair value changes of financial instruments, and reversal of impairment provisions for receivables, with no reclassification of non-recurring items as recurring Non-Recurring Gains and Losses and Amounts | Item | Amount (RMB) | | :--- | :--- | | Gains or losses from disposal of non-current assets | 526,071.80 | | Government grants recognized in profit or loss (excluding those closely related to the company's normal business operations and continuously enjoyed) | 349,253.47 | | Gains or losses from changes in fair value of financial assets and liabilities held by non-financial enterprises, and investment gains from disposal of financial assets and liabilities | 7,243,038.22 | | Reversal of impairment provisions for receivables that are individually tested for impairment | 332,644.18 | | Other non-operating income and expenses apart from the above | 461,858.13 | | Less: Income tax impact | 1,305,359.10 | | Minority interest impact (after tax) | 20,232.37 | | **Total** | **7,587,274.33** | - The company does not classify non-recurring gains and losses as recurring gains and losses[30](index=30&type=chunk) Management Discussion and Analysis [Main Business Activities During the Reporting Period](index=11&type=section&id=I.%20Main%20Business%20Activities%20During%20the%20Reporting%20Period) As a leading provider of dental restoration materials and digital dental equipment, the company achieved rapid business growth through technological innovation, global expansion, and customer loyalty optimization, with operating revenue increasing by 17.22% during the reporting period - The company is a leading domestic supplier of dental restoration materials and digital dental equipment, dedicated to independent R&D, production, and sales of zirconia ceramic blocks and other dental restoration materials, as well as designing and selling digital dental equipment[41](index=41&type=chunk) - The company provides one-stop digital dental comprehensive services for dental laboratories and dental medical institutions, with products exported to markets in Europe, America, Japan, and South Korea[42](index=42&type=chunk)[43](index=43&type=chunk) Operating Revenue Growth During the Reporting Period | Indicator | Amount (RMB) | YoY Growth | | :--- | :--- | :--- | | Operating Revenue | 485,801,461.65 | 17.22% | [Industry Overview and Company Position](index=11&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89Industry%20Overview%20and%20Company%20Position) The dental consumables and digital dental equipment industry is growing steadily, with the Chinese market projected to reach **166.7 billion RMB by 2030**, driven by policy support, an aging population, health awareness, technological advancements, and accelerated domestic substitution, positioning the company as a leader despite innovation and competition risks - The global dental medical device market is projected to reach **$83.7 billion by 2030**, with the Chinese market expected to reach **166.7 billion RMB**[34](index=34&type=chunk) - Key industry growth drivers include national policy support, an aging population, increased health awareness, technological advancements like 3D printing/CAD/CAM, and accelerated domestic substitution[35](index=35&type=chunk)[36](index=36&type=chunk) - The company holds a leading position in dental restoration materials and digital equipment but faces risks from technological innovation and intensifying market competition[39](index=39&type=chunk)[40](index=40&type=chunk) [Overview of Company's Main Business](index=12&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89Overview%20of%20Company%27s%20Main%20Business) Since its establishment in 2007, the company has focused on independent R&D, production, and sales of dental restoration materials (e.g., zirconia ceramic blocks) and digital dental equipment, providing one-stop digital dental services to laboratories and clinics, with a global presence and a commitment to building a smart dental ecosystem through digital transformation - The company's main business is as a supplier of dental restoration materials and digital dental equipment, dedicated to independent R&D, production, and sales of zirconia ceramic blocks and other materials[41](index=41&type=chunk) - The company offers two main product categories: dental restoration materials and digital dental equipment, developing chairside restoration systems and invisible orthodontic solutions to meet dentists' needs[42](index=42&type=chunk)[43](index=43&type=chunk) - The company's business covers major provinces, municipalities, and autonomous regions nationwide, with products exported to key markets in Europe, America, Japan, and South Korea, building new cooperative business models through digital dentistry[43](index=43&type=chunk) [Company Business and Main Products or Services](index=13&type=section&id=%EF%BC%88%E4%B8%89%EF%BC%89Company%20Business%20and%20Main%20Products%20or%20Services) The company's main products include dental restoration materials (e.g., zirconia, glass ceramics, resin blocks, elastic ceramics, additive manufacturing resins) and digital dental equipment (e.g., intraoral scanners, milling machines, sintering furnaces, 3D printers), along with implants and surgical kits, contributing to a 17.22% increase in operating revenue during the reporting period - The company's products primarily include dental restoration materials (zirconia ceramic blocks, glass ceramic blocks, millable resin blocks, elastic ceramics, additive manufacturing resins) and digital dental equipment (intraoral scanners, milling equipment, sintering equipment, 3D printers)[45](index=45&type=chunk)[46](index=46&type=chunk)[47](index=47&type=chunk) - The company also provides dental implants (IU implants, IT implants) and implant surgical kits, suitable for dental implantology[47](index=47&type=chunk)[48](index=48&type=chunk) Operating Revenue During the Reporting Period | Indicator | Amount (RMB) | | :--- | :--- | | Operating Revenue | 485,801,461.65 | [Company's Main Business Operating Model](index=16&type=section&id=%EF%BC%88%E5%9B%9B%EF%BC%89Company%27s%20Main%20Business%20Operating%20Model) The company employs a "production-to-order combined with stock production" model for core products, a categorized procurement approach with dynamic safety stock and regular supplier evaluations, a "direct sales + distribution" model for sales, and a market-driven R&D strategy with multi-departmental collaboration and external partnerships - The company's production model combines "production-to-order and stock production," possessing an independent production system[49](index=49&type=chunk) - The procurement model categorizes and controls materials, adopting quantitative irregular procurement, and strictly evaluating suppliers[51](index=51&type=chunk) - The sales model is "direct sales + distribution," primarily direct sales domestically, and mainly distribution internationally, with market development through exhibitions, advertising, and training[52](index=52&type=chunk) - The R&D model is market-oriented, formulating medium- and long-term plans, establishing product development teams, and forming a multi-departmental collaborative development process[53](index=53&type=chunk) [Key Drivers of Company Performance During the Reporting Period](index=17&type=section&id=%EF%BC%88%E4%BA%94%EF%BC%89Key%20Drivers%20of%20Company%20Performance%20During%20the%20Reporting%20Period) The company's performance growth is primarily driven by technological innovation, product upgrades, synergistic effects of digital dental equipment and restoration materials, increasing market demand from an aging population and health awareness, global expansion, rising penetration of digital restoration materials like zirconia, and enhanced customer loyalty through one-stop solutions and localized services - Technological innovation, product upgrades, and digital transformation are core drivers, with digital dental equipment and restoration materials forming synergistic effects[54](index=54&type=chunk) - Market demand growth stems from an aging population, increased health awareness, and domestic implant centralized procurement policies, with the company completing its implant system layout through the acquisition of Warantec Korea[55](index=55&type=chunk) - Global layout and expansion into emerging markets (Europe, America, Japan, South Korea, Southeast Asia, Middle East, Australia, etc.) are important growth drivers[56](index=56&type=chunk)[57](index=57&type=chunk) - Digital restoration materials like zirconia and glass ceramics continue to replace traditional materials, and the increasing penetration rate of dental implants (China's 5%-10% is far below the international 20%+) expands the market[58](index=58&type=chunk) - The company enhances customer stickiness by providing one-stop solutions and localized services and training[59](index=59&type=chunk)[60](index=60&type=chunk) [Medical Device Registration Certificates](index=18&type=section&id=%EF%BC%88%E5%85%AD%EF%BC%89Medical%20Device%20Registration%20Certificates) As of June 30, 2025, the company has multiple medical device products under registration application in China, the US, and the EU, covering dental ceramic blocks, resin cements, adhesives, additive manufacturing resins, intraoral scanners, and implants, while already holding numerous NMPA, FDA, and CE certificates, with zirconia ceramic blocks and staining liquids being key revenue drivers - As of June 30, 2025, the company has **8 medical devices** under registration application in China, including dental ceramic blocks, resin cements for bonding, dental adhesives, additive manufacturing (light-cured) crown and bridge resins, oral digital impression scanners, custom denture porcelain powder, pit and fissure sealants, abutments, and accessories[61](index=61&type=chunk)[62](index=62&type=chunk) - In the United States and the European Union, the company has **14 medical devices** under registration application, including dental adhesives, preformed polymer-based crown and bridge materials, staining liquids for all-ceramic dentures, dental base resins, resin-based dental cements for bonding, dental glass ceramic blocks, additive manufacturing (light-cured) crown and bridge resins, custom denture porcelain powder, temporary crown and bridge resins, all-ceramic denture zirconia ceramic blocks, Aidite dental zirconia ceramic block specific staining liquids, additive manufacturing (light-cured) orthodontic resins, endosseous implant systems, and non-sterile and reusable dental surgical instruments and tool kits[63](index=63&type=chunk)[64](index=64&type=chunk)[65](index=65&type=chunk)[66](index=66&type=chunk) - The company has obtained multiple NMPA, FDA, and CE registration certificates, with all-ceramic denture zirconia ceramic blocks and staining liquids being products accounting for **over 10% of main business revenue**[68](index=68&type=chunk)[72](index=72&type=chunk)[78](index=78&type=chunk)[80](index=80&type=chunk) [Analysis of Core Competencies](index=35&type=section&id=II.%20Analysis%20of%20Core%20Competencies) The company's core competencies stem from deep R&D accumulation, continuous investment in innovation, a comprehensive dental ecosystem, globally extensive sales and customer service, numerous domestic and international certifications, strong brand advantages, and a professional and stable management team - The company has profound R&D accumulation, has been continuously recognized as a National High-Tech Enterprise, holds **163 valid patents**, and has established partnerships with renowned universities such as Peking University School of Stomatology and West China Hospital of Stomatology, Sichuan University[82](index=82&type=chunk)[83](index=83&type=chunk)[84](index=84&type=chunk) - The company actively embraces digital transformation, launching integrated services for laboratory and clinical products, creating a dental ecosystem closed-loop, and offering solutions such as rapid aesthetic restoration, digital full dentures, chairside restoration systems, and invisible orthodontics[85](index=85&type=chunk) - The company's sales system has deep global coverage, with subsidiaries in the United States, Germany, South Korea, and Japan, technical service teams in India, the Middle East, Australia, and South America, and long-term partnerships with leading global dental laboratories[86](index=86&type=chunk) - The company has established a comprehensive, end-to-end service system, providing on-site product application training, after-sales support, and digital talent development to enhance customer loyalty[87](index=87&type=chunk) - The company holds multiple domestic and international medical device production licenses, operating licenses, ISO13485, MDSAP, EU CE certification, US FDA certification, and other qualifications, building competitive barriers[88](index=88&type=chunk) - The company possesses a professional and stable management team, adhering to the mission of "enabling everyone to have good teeth," and is committed to building a smart dental ecosystem[89](index=89&type=chunk) [Analysis of Main Business Operations](index=38&type=section&id=III.%20Analysis%20of%20Main%20Business%20Operations) Aidite's main business achieved steady growth during the reporting period, with operating revenue reaching **485.80 million RMB**, a 17.22% increase, and net profit attributable to shareholders of **92.04 million RMB**, up 19.86%, driven by optimized product structure, enhanced brand penetration, and increased R&D investment, with future plans for global expansion and strategic M&A to build a smart dental ecosystem Main Financial Performance During the Reporting Period | Indicator | Amount (billion RMB) | YoY Growth | | :--- | :--- | :--- | | Operating Revenue | 0.486 | 17.22% | | Net Profit Attributable to Shareholders of Listed Company | 0.092 | 19.86% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Items) | 0.084 | 9.35% | - In Q2 2025, the company achieved operating revenue of **280 million RMB**, a **16.61% YoY increase**, with revenue expected to maintain a continuous growth trend[91](index=91&type=chunk) [1. Operating Performance of Main Products](index=38&type=section&id=1.%20Operating%20Performance%20of%20Main%20Products) During the reporting period, dental restoration materials business generated **358 million RMB** in revenue, growing by 19.19% and accounting for 73.74% of total revenue, while digital dental equipment business reached **96 million RMB**, up 3.64% and representing 19.80% of total revenue, with the company obtaining 9 new medical device registration certificates and planning continued R&D innovation Operating Performance of Main Products | Business Segment | Operating Revenue (million RMB) | YoY Growth | Proportion of Total Revenue | | :--- | :--- | :--- | :--- | | Dental Restoration Materials | 358 | 19.19% | 73.74% | | Digital Dental Equipment | 96 | 3.64% | 19.80% | - The company obtained **9 new NMPA, FDA, and CE Class II and Class III medical device registration certificates** during the reporting period[92](index=92&type=chunk) - The company will continue to drive product iteration through innovative R&D, increase investment in R&D and market promotion based on differentiated global market demands, and focus on building new quality productive forces for high-end dental restoration materials[92](index=92&type=chunk) [2. Profitability](index=38&type=section&id=2.%20Profitability) During the reporting period, the company's profitability showed divergence, with dental restoration materials' gross margin at 58.20% (down 2.17% due to discount adjustments for market share), while digital equipment's gross margin rose to 30.50% (up 1.24% from product iteration and optimized operations), reflecting overall revenue and profit growth Gross Margin of Main Businesses | Business Segment | Gross Margin Current Period | Gross Margin Prior Year | Change in Gross Margin from Prior Year | | :--- | :--- | :--- | :--- | | Dental Restoration Materials | 58.20% | 60.36% | -2.17% | | Digital Dental Equipment | 30.50% | 29.26% | 1.24% | - The decrease in gross margin for dental restoration materials was primarily due to the company adjusting its discount framework to increase market share[94](index=94&type=chunk) - The increase in gross margin for digital equipment business benefited from continuous product iteration, optimized product structure, and refined operational management[95](index=95&type=chunk) [3. Future Development Outlook](index=39&type=section&id=3.%20Future%20Development%20Outlook) The company sees broad market potential for its dental medical device products and plans to continuously enhance R&D for clinical products and materials, digital technology development, market promotion, and supply chain synergy, while actively seeking M&A opportunities to build a smart dental ecosystem - The company's dental medical device products feature rigid demand, high frequency of use, and wide application, with broad market potential both domestically and internationally[96](index=96&type=chunk) - In the future, the company will enhance its R&D capabilities for clinical products and materials, digital technology development, market promotion, and supply chain synergy[96](index=96&type=chunk) - The company will actively seek external M&A opportunities, committed to building a smart dental ecosystem[96](index=96&type=chunk) [YoY Changes in Key Financial Data](index=39&type=section&id=YoY%20Changes%20in%20Key%20Financial%20Data) During the reporting period, operating revenue, operating costs, sales expenses, administrative expenses, and R&D investment all increased year-on-year, with administrative expenses and R&D investment seeing significant growth of 44.13% and 36.12% respectively, while financial expenses decreased sharply by 343.24% due to exchange gains, and net cash flow from operating activities surged by 141.72% YoY Changes in Key Financial Data | Indicator | Current Period (RMB) | Prior Year (RMB) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 485,801,461.65 | 414,434,257.54 | 17.22% | | | Operating Cost | 233,461,034.91 | 196,121,026.92 | 19.04% | | | Sales Expenses | 97,664,688.15 | 79,167,879.84 | 23.36% | | | Administrative Expenses | 40,564,242.39 | 28,143,237.92 | 44.13% | Primarily due to increased employee compensation for new hires and amortization of intangible assets | | Financial Expenses | -12,612,150.38 | -2,845,466.29 | -343.24% | Primarily due to exchange gains | | R&D Investment | 28,255,045.70 | 20,757,904.01 | 36.12% | Primarily due to increased R&D personnel and new product registration fees | | Net Cash Flow from Operating Activities | 79,153,449.17 | 32,745,614.35 | 141.72% | Primarily due to increased cash received from sales and increased tax refunds in the current period | | Net Cash Flow from Investing Activities | 42,712,833.80 | 75,822,891.39 | -43.67% | Primarily due to cash management activities in the current period | | Net Cash Flow from Financing Activities | -50,087,879.44 | 793,794,773.64 | -106.31% | Primarily due to IPO proceeds received in the prior year and dividend payments in the current period | | Net Increase in Cash and Cash Equivalents | 73,673,197.25 | 900,045,761.45 | -91.81% | Primarily due to IPO proceeds received in the prior year | [Products or Services Accounting for Over 10% of Revenue](index=39&type=section&id=Products%20or%20Services%20Accounting%20for%20Over%2010%25%20of%20Revenue) During the reporting period, dental restoration materials and digital dental equipment were the company's main products, with dental restoration materials revenue growing by 19.19% but gross margin decreasing by 2.17% to 58.20%, while digital dental equipment revenue increased by 3.64% and gross margin improved by 1.24% to 30.50% Products or Services Accounting for Over 10% of Revenue | Product or Service | Operating Revenue (RMB) | Operating Cost (RMB) | Gross Margin | YoY Change in Operating Revenue | YoY Change in Operating Cost | YoY Change in Gross Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Dental Restoration Materials | 358,234,768.21 | 149,759,920.15 | 58.20% | 19.19% | 25.70% | -2.17% | | Digital Dental Equipment | 96,186,861.81 | 66,848,022.15 | 30.50% | 3.64% | 1.83% | 1.24% | [Analysis of Non-Core Business Operations](index=40&type=section&id=IV.%20Analysis%20of%20Non-Core%20Business%20Operations) Non-core business activities during the reporting period included investment income, fair value changes, asset impairment, non-operating income/expenses, other income, and credit impairment losses, with investment income and fair value changes being sustainable due to investments in associates and cash management, while government grants are non-recurring but VAT super deduction for advanced manufacturing is sustainable Analysis of Non-Core Business Operations | Item | Amount (RMB) | Proportion of Total Profit | Reason for Formation | Sustainability | | :--- | :--- | :--- | :--- | :--- | | Investment Income | 8,220,483.39 | 8.21% | Primarily from investment income from associates and cash management income in the current period | Yes | | Gains or Losses from Changes in Fair Value | 1,697,502.04 | 1.69% | Primarily from cash management income in the current period | Yes | | Asset Impairment | -1,997,886.30 | -1.99% | Primarily due to provision for inventory depreciation | Yes | | Non-Operating Income | 580,515.88 | 0.58% | | No | | Non-Operating Expenses | 118,657.75 | 0.12% | | No | | Other Income | 618,458.43 | 0.62% | Primarily from government grants and VAT super deduction for advanced manufacturing enterprises | Government grants are not sustainable, VAT super deduction for advanced manufacturing enterprises is sustainable | | Credit Impairment Losses | -3,805,339.16 | -3.80% | Primarily due to provision for bad debts on accounts receivable | Yes | | Gains from Disposal of Assets | 526,071.80 | 0.53% | | No | [Analysis of Assets and Liabilities](index=40&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) At the end of the reporting period, total assets increased by 3.62% and net assets attributable to shareholders by 2.32%, with growth in monetary funds, accounts receivable, inventory, long-term equity investments, construction in progress, and right-of-use assets, while liabilities such as short-term borrowings, contract liabilities, and lease liabilities also increased, and fair value financial assets totaled **743 million RMB**, with restricted assets mainly comprising electronic account and litigation deposits Significant Changes in Asset Composition | Item | Amount at End of Current Period (RMB) | Proportion of Total Assets | Amount at End of Prior Year (RMB) | Proportion of Total Assets | Change in Proportion | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Monetary Funds | 768,344,713.99 | 32.41% | 694,354,784.44 | 30.35% | 2.06% | Primarily due to increased cash received from sales | | Accounts Receivable | 225,934,686.43 | 9.53% | 174,749,008.58 | 7.64% | 1.89% | Primarily due to natural growth from business expansion and moderately increased credit limits for customers with good credit standing | | Inventory | 171,141,579.49 | 7.22% | 163,198,537.47 | 7.13% | 0.09% | Primarily due to the company proactively increasing safety stock to avoid potential supply chain instability caused by international market policies | | Long-term Equity Investments | 60,355,228.07 | 2.55% | 53,644,122.87 | 2.34% | 0.21% | Primarily due to increased operating results, such as net profit, of the company's associate, Jingdezhen Wanwei New Material Co., Ltd. | | Construction in Progress | 4,914,910.35 | 0.21% | 0.00 | 0.00% | 0.21% | Primarily due to investment in the dental industrial park construction project | | Right-of-Use Assets | 13,511,867.68 | 0.57% | 7,264,964.67 | 0.32% | 0.25% | Primarily due to subsidiaries expanding production and delivery capabilities by leasing factories and warehouses | | Short-term Borrowings | 1,502,250.00 | 0.06% | 0.00 | 0.00% | 0.06% | Primarily due to operating loans of non-wholly owned subsidiaries | | Contract Liabilities | 36,247,197.69 | 1.53% | 31,187,503.74 | 1.36% | 0.17% | Primarily due to overseas sales where cash has been received but goods have not yet been shipped or customs declared | | Lease Liabilities | 9,413,735.12 | 0.40% | 4,748,976.32 | 0.21% | 0.19% | Primarily due to subsidiaries expanding production and delivery capabilities by leasing factories and warehouses | Fair Value of Financial Assets at Period-End | Item | Period-End Amount (RMB) | | :--- | :--- | | Trading Financial Assets | 742,697,502.04 | | Receivables Financing | 50,303.00 | | **Total** | **742,747,805.04** | Restricted Assets | Item | Period-End Book Value (RMB) | Reason for Restriction | | :--- | :--- | :--- | | Monetary Funds | 4,672,710.49 | Electronic account deposit, litigation deposit | [Analysis of Investment Status](index=42&type=section&id=VI.%20Analysis%20of%20Investment%20Status) During the reporting period, the company's total investment significantly increased by 1046.90%, primarily due to cash management activities, with fair value financial assets totaling **743 million RMB** at period-end, and **181 million RMB** of raised funds cumulatively used, including **371 million RMB** for cash management, with all raised fund investment projects progressing as planned Investment Amount During the Reporting Period | Indicator | Investment Amount Current Period (RMB) | Investment Amount Prior Year (RMB) | Change Rate | | :--- | :--- | :--- | :--- | | Investment Amount | 1,999,801,733.38 | 174,365,214.04 | 1,046.90% | Financial Assets Measured at Fair Value | Asset Category | Period-End Amount (RMB) | | :--- | :--- | | Other (primarily trading financial assets and receivables financing) | 742,747,805.04 | - The company cumulatively used **180.77 million RMB** of raised funds, with a cash management balance of **371 million RMB**[116](index=116&type=chunk) - The pledged raised fund projects include Aidite Dental Industrial Park - Oral CAD/CAM Material Industrialization Project, Digital Oral Comprehensive Service Platform Project, Aidite Dental Industrial Park - R&D Pilot Base Project, and supplementary working capital, all progressing as planned without significant changes[118](index=118&type=chunk)[119](index=119&type=chunk) Entrusted Wealth Management Status | Specific Type | Entrusted Wealth Management Amount (million RMB) | Unexpired Balance (million RMB) | | :--- | :--- | :--- | | Bank Wealth Management Products | 492.08 | 543.47 | | Brokerage Wealth Management Products (own funds) | 70.00 | 70.00 | | Brokerage Wealth Management Products (raised funds) | 371.61 | 371.00 | | **Total** | **933.69** | **984.47** | [1. Overall Situation](index=42&type=section&id=1.%20Overall%20Situation) During the reporting period, the company's total investment amounted to **1.9998 billion RMB**, representing a substantial increase of 1,046.90% compared to the previous year Investment Amount During the Reporting Period | Indicator | Investment Amount Current Period (RMB) | Investment Amount Prior Year (RMB) | Change Rate | | :--- | :--- | :--- | :--- | | Investment Amount | 1,999,801,733.38 | 174,365,214.04 | 1,046.90% | [2. Significant Equity Investments Acquired During the Reporting Period](index=42&type=section&id=2.%20Significant%20Equity%20Investments%20Acquired%20During%20the%20Reporting%20Period) The company did not acquire any significant equity investments during the reporting period - The company had no significant equity investments during the reporting period[111](index=111&type=chunk) [3. Significant Non-Equity Investments in Progress During the Reporting Period](index=42&type=section&id=3.%20Significant%20Non-Equity%20Investments%20in%20Progress%20During%20the%20Reporting%20Period) The company had no significant non-equity investments in progress during the reporting period - The company had no significant non-equity investments during the reporting period[111](index=111&type=chunk) [4. Financial Assets Measured at Fair Value](index=42&type=section&id=4.%20Financial%20Assets%20Measured%20at%20Fair%20Value) At the end of the reporting period, the company's financial assets measured at fair value totaled **743 million RMB**, primarily comprising other assets funded by both own capital and raised funds Financial Assets Measured at Fair Value | Asset Category | Period-End Amount (RMB) | Source of Funds | | :--- | :--- | :--- | | Other | 742,747,805.04 | Own funds/Raised funds | [5. Use of Raised Funds](index=42&type=section&id=5.%20Use%20of%20Raised%20Funds) The company raised **761.32 million RMB** net from its IPO in June 2024, and as of June 30, 2025, cumulatively used **180.77 million RMB**, with **371 million RMB** allocated to cash management, and all raised fund investment projects, including the dental industrial park and digital service platform, are progressing as planned without significant changes - The company's net proceeds from its initial public offering in June 2024 amounted to **761.32 million RMB**[114](index=114&type=chunk) - As of June 30, 2025, the company cumulatively used **180.77 million RMB** of raised funds, with a cash management balance of **371 million RMB**[116](index=116&type=chunk) Status of Pledged Raised Fund Projects | Project Name | Pledged Investment Amount (million RMB) | Cumulative Investment Amount as of Period-End (million RMB) | Investment Progress as of Period-End | | :--- | :--- | :--- | :--- | | Aidite Dental Industrial Park - Oral CAD/CAM Material Industrialization Project | 235.32 | 41.37 | 17.58% | | Digital Oral Comprehensive Service Platform Project | 264.47 | 11.28 | 4.26% | | Aidite Dental Industrial Park - R&D Pilot Base Project | 168.74 | 35.33 | 20.94% | | Supplementary Working Capital | 92.79 | 92.79 | 100.00% | - All raised fund investment projects have reached their planned progress, and the project feasibility has not undergone significant changes[119](index=119&type=chunk) [6. Entrusted Wealth Management, Derivative Investments, and Entrusted Loans](index=47&type=section&id=6.%20Entrusted%20Wealth%20Management%2C%20Derivative%20Investments%2C%20and%20Entrusted%20Loans) During the reporting period, the company's total entrusted wealth management amounted to **933.69 million RMB**, with an unexpired balance of **984.47 million RMB**, primarily in bank and brokerage wealth management products, with no overdue unrecovered amounts, and no derivative investments or entrusted loans Entrusted Wealth Management Status | Specific Type | Entrusted Wealth Management Amount (million RMB) | Unexpired Balance (million RMB) | | :--- | :--- | :--- | | Bank Wealth Management Products | 492.08 | 543.47 | | Brokerage Wealth Management Products (own funds) | 70.00 | 70.00 | | Brokerage Wealth Management Products (raised funds) | 371.61 | 371.00 | | **Total** | **933.69** | **984.47** | - The company had no derivative investments or entrusted loans during the reporting period[124](index=124&type=chunk)[125](index=125&type=chunk) [Significant Asset and Equity Disposals](index=47&type=section&id=VII.%20Significant%20Asset%20and%20Equity%20Disposals) The company did not undertake any significant asset or equity disposals during the reporting period - The company did not dispose of any significant assets during the reporting period[126](index=126&type=chunk) - The company did not dispose of any significant equity during the reporting period[127](index=127&type=chunk) [Analysis of Major Holding and Participating Companies](index=48&type=section&id=VIII.%20Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) The company has no major holding or participating company information requiring disclosure during the reporting period - The company had no major holding or participating company information requiring disclosure during the reporting period[127](index=127&type=chunk) [Information on Structured Entities Controlled by the Company](index=48&type=section&id=IX.%20Information%20on%20Structured%20Entities%20Controlled%20by%20the%20Company) The company did not control any structured entities during the reporting period - The company did not control any structured entities during the reporting period[128](index=128&type=chunk) [Risks Faced by the Company and Countermeasures](index=48&type=section&id=X.%20Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) The company faces multiple risks including exchange rate fluctuations, customer dispersion, business compliance, technological innovation, international market policy changes, and accounts receivable collection, for which it has implemented countermeasures such as exchange rate risk management, customer and market expansion, compliance training, continuous innovation, diversified international market布局, and strengthened accounts receivable management - The company has a high proportion of overseas revenue, and exchange rate fluctuations may affect the price competitiveness of export products and exchange gains/losses; exchange gains for the reporting period were **11.95 million RMB**. Countermeasures include adjusting settlement currencies and payment terms, and hedging risks through forward foreign exchange settlements[128](index=128&type=chunk) - The company has a large number of customers, and customer dispersion risk may increase the difficulty of customer relationship maintenance. Countermeasures include actively expanding new customers and markets, increasing product diversification, and establishing long-term cooperative relationships[129](index=129&type=chunk) - The company's business involves multi-country regulation, posing a risk of non-compliance penalties due to misunderstanding policies. Countermeasures include regular compliance training, risk assessment, contract review, and continuous improvement of the compliance management system[130](index=130&type=chunk)[131](index=131&type=chunk) - The dental consumables and digital equipment industry is rapidly developing, with high technological innovation risk. Countermeasures include in-depth market research, patent application, and expanding collaborative R&D projects[132](index=132&type=chunk) - Changes in international market trade rules, technical standards, and regulatory requirements may lead to increased export costs. Countermeasures include establishing a dynamic policy monitoring mechanism, researching local regulatory policies, enhancing product added value, and diversifying overseas market layouts[133](index=133&type=chunk) - At the end of the reporting period, the book value of accounts receivable was **226 million RMB**, accounting for **46.51% of operating revenue**, posing collection risks. Countermeasures include strengthening financial management systems and effectively managing customer credit terms[134](index=134&type=chunk) [Registration Form for Investor Relations Activities During the Reporting Period](index=50&type=section&id=XI.%20Registration%20Form%20for%20Investor%20Relations%20Activities%20During%20the%20Reporting%20Period) During the reporting period, the company hosted 7 investor relations activities, including on-site visits and online exchanges, primarily with institutional and individual investors, with details available on Juchao Information Network - During the reporting period, the company hosted **7 investor relations activities**, including on-site visits and online platform exchanges[135](index=135&type=chunk) - The attendees were primarily institutional and individual investors, with discussion content and research indexes available on Juchao Information Network[135](index=135&type=chunk) [Formulation and Implementation of Market Value Management System and Valuation Enhancement Plan](index=51&type=section&id=XII.%20Formulation%20and%20Implementation%20of%20Market%20Value%20Management%20System%20and%20Valuation%20Enhancement%20Plan) The company did not formulate a market value management system or disclose a valuation enhancement plan during the reporting period - The company did not formulate a market value management system during the reporting period[137](index=137&type=chunk) - The company did not disclose a valuation enhancement plan during the reporting period[137](index=137&type=chunk) [Implementation of "Dual Improvement in Quality and Returns" Action Plan](index=51&type=section&id=XIII.%20%22Dual%20Improvement%20in%20Quality%20and%20Returns%22%20Action%20Plan%20Implementation) The company did not disclose an announcement regarding the "Dual Improvement in Quality and Returns" action plan during the reporting period - The company did not disclose an announcement regarding the "Dual Improvement in Quality and Returns" action plan during the reporting period[137](index=137&type=chunk) Corporate Governance, Environment, and Society [Changes in Company Directors, Supervisors, and Senior Management](index=51&type=section&id=I.%20Changes%20in%20Company%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, there was a change in the company's senior management, with Feng Aihua appointed as Deputy General Manager and Xie Wandong dismissed from the position due to personal reasons Changes in Directors, Supervisors, and Senior Management | Name | Position | Type | Date | Reason | | :--- | :--- | :--- | :--- | :--- | | Feng Aihua | Deputy General Manager | Appointment | April 28, 2025 | Job transfer | | Xie Wandong | Deputy General Manager | Dismissal | June 03, 2025 | Personal reasons | [Profit Distribution and Capital Reserve to Share Capital Transfer in Current Period](index=51&type=section&id=II.%20Profit%20Distribution%20and%20Capital%20Reserve%20to%20Share%20Capital%20Transfer%20in%20Current%20Period) The company plans no interim cash dividends, bonus shares, or capital increase from capital reserves - The company plans no interim cash dividends, bonus shares, or capital increase from capital reserves[139](index=139&type=chunk) [Implementation of Company Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=51&type=section&id=III.%20Implementation%20of%20Company%20Equity%20Incentive%20Plans%2C%20Employee%20Stock%20Ownership%20Plans%2C%20or%20Other%20Employee%20Incentive%20Measures) The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures implemented during the reporting period - The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures and their implementation during the reporting period[140](index=140&type=chunk) [Environmental Information Disclosure](index=51&type=section&id=IV.%20Environmental%20Information%20Disclosure) The listed company and its major subsidiaries are not included in the list of enterprises required to disclose environmental information by law - The listed company and its major subsidiaries are not included in the list of enterprises required to disclose environmental information by law[141](index=141&type=chunk) [Social Responsibility](index=51&type=section&id=V.%20Social%20Responsibility) Guided by its mission "to enable everyone to have good teeth," the company actively fulfills its social responsibilities by protecting shareholder and employee rights, maintaining robust supply chain and quality management, ensuring production safety, promoting environmental protection through green initiatives, and engaging in extensive public welfare activities, including free dental services for children - The company adheres to the mission of "enabling everyone to have good teeth" and embraces core values including creating value for customers, being fighter-oriented, self-reflection, innovation, integrity, and cooperation[141](index=141&type=chunk) [1. Company's Purpose and Philosophy for Fulfilling Social Responsibility](index=51&type=section&id=1.%20Company%27s%20Purpose%20and%20Philosophy%20for%20Fulfilling%20Social%20Responsibility) The company's mission is "to enable everyone to have good teeth," guided by core values of creating customer value, being fighter-oriented, self-reflection, innovation, integrity, and cooperation, aiming to build a smart dental ecosystem through technological innovation and digital transformation - The company's mission is "to enable everyone to have good teeth," with core values including creating value for customers, being fighter-oriented, self-reflection, innovation, integrity, and cooperation[141](index=141&type=chunk) - The company's vision is "to bring digitalization and intelligence to every dental institution and practitioner, building a smart dental ecosystem"[142](index=142&type=chunk) [2. Shareholder Rights Protection](index=52&type=section&id=2.%20Shareholder%20Rights%20Protection) The company strictly adheres to laws, regulations, and its articles of association, operating in a standardized manner and fulfilling information disclosure obligations truthfully, accurately, completely, timely, and fairly, including the implementation of the 2024 annual equity distribution on June 10, 2025, with a cash dividend of **6.5 RMB per 10 shares** and a capital reserve transfer of **4 shares for every 10 shares** - The company strictly complies with laws and regulations, operates in a standardized manner, and fairly fulfills its information disclosure obligations[143](index=143&type=chunk) - On June 10, 2025, the company implemented its 2024 annual equity distribution, distributing a cash dividend of **RMB 6.5 (tax inclusive) per 10 shares** and transferring **4 shares for every 10 shares** from capital reserves to all shareholders[143](index=143&type=chunk) [3. Employee Rights Protection](index=52&type=section&id=3.%20Employee%20Rights%20Protection) The company actively expands employment, optimizes recruitment, provides training and development, strictly adheres to labor laws, ensures employee benefits and social security, pays housing provident funds, offers health check-ups, continuously improves compensation and incentive systems, prioritizes safety production with no major industrial accidents, and has established an "Employee Welfare Management System" - The company actively recruits employees, provides training and development channels, strictly complies with labor laws and regulations, and protects employee rights[144](index=144&type=chunk) - The company implements a social security system, paying endowment, medical, unemployment, maternity, and work-related injury insurance, as well as housing provident funds for employees, and regularly provides health check-up benefits[144](index=144&type=chunk) - The company highly values safety production, implements national safety production policies, has not experienced any major industrial accidents, and has established an "Employee Welfare Management System"[144](index=144&type=chunk) [4. Supplier and Customer Rights Protection](index=52&type=section&id=4.%20Supplier%20and%20Customer%20Rights%20Protection) The company has established a comprehensive supply chain management system, fairly evaluating and selecting suppliers, building long-term strategic partnerships, prioritizing product quality with ISO13485 and MDSAP certifications, ensuring timely payment to suppliers, standardizing bidding processes, signing "Integrity Agreements," and communicating social responsibility principles to partners - The company has built a comprehensive supply chain management system, fairly evaluating and selecting suppliers, and establishing long-term strategic partnerships with multiple suppliers[145](index=145&type=chunk) - The company highly values product quality, strictly controlling it from the raw material end, and has obtained ISO13485 and MDSAP certificates[145](index=145&type=chunk) - The company protects the legitimate rights and interests of suppliers, promptly pays procurement funds, standardizes bidding processes, signs "Integrity Agreements," and communicates social responsibility concepts to partners[145](index=145&type=chunk)[146](index=146&type=chunk) [5. Risk Prevention and Safety Production](index=53&type=section&id=5.%20Risk%20Prevention%20and%20Safety%20Production) The company prevents violations and risks through regular self-inspections, employee reporting mechanisms, and internal control department evaluations, ensuring production safety with comprehensive pre-event, in-process, and post-event supervision via "Safety Operation Manuals" and on-site inspections, with no production safety accidents reported during the period - The company prevents violations and risk events through regular self-inspections, employee reporting and internal control department evaluations[147](index=147&type=chunk) - The company achieves comprehensive supervision of production safety through systems like the "Safety Operation Manual" and on-site inspections[147](index=147&type=chunk) - No production safety accidents occurred during the reporting period[147](index=147&type=chunk) [6. Environmental Protection](index=53&type=section&id=6.%20Environmental%20Protection) The company continuously improves environmental governance regulations, actively upgrades factory equipment, establishes an "Energy Saving and Emission Reduction Management System," achieves an "leading" environmental performance rating for its zirconia production line, and invests in green, low-carbon factory construction and photovoltaic power generation facilities for its raised fund projects to build a zero-carbon industrial park - The company continuously improves environmental governance regulations, establishes an "Energy Saving and Emission Reduction Management System," and integrates environmental governance into its operational processes[148](index=148&type=chunk) - The company's zirconia production line has an environmental performance rating of "leading," and other products are listed as orange alert environmental control exemption units[148](index=148&type=chunk) - The company invests in green and low-carbon factory construction on land for raised fund projects, invests in photovoltaic power generation facilities, and builds a zero-carbon industrial park[148](index=148&type=chunk) [7. Actively Engaging in Social Welfare Activities](index=54&type=section&id=7.%20Actively%20Engaging%20in%20Social%20Welfare%20Activities) The company's subsidiary, Naji Oral Technology Qinhuangdao Co., Ltd., continuously conducts "Mountain Daisies, Building Dreams Together" charity events, providing free dental fluoride application services to **7,246 children** in various regions, and also organized 25 "Healthy Oral Cavity Miles" events, offering free fluoride and plaque detection services to **over 40,000 children** in 54 cities nationwide, along with oral health education - Subsidiary Naji Oral Technology Qinhuangdao Co., Ltd. carried out the "Mountain Daisies, Building Dreams Together" public welfare activity, providing free dental fluoride application services to **7,246 children**[150](index=150&type=chunk) - The company conducted **25 "Healthy Oral Cavity Miles into Kindergartens" public welfare activities**, providing free dental fluoride application and plaque detection services to **over 40,000 children** in **54 cities nationwide**, along with oral health science education[150](index=150&type=chunk) Significant Matters [Commitments Fulfilled and Overdue Unfulfilled by Actual Controllers, Shareholders, Related Parties, Acquirers, and the Company During and as of the End of the Reporting Period](index=55&type=section&id=I.%20Commitments%20Fulfilled%20and%20Overdue%20Unfulfilled%20by%20Actual%20Controllers%2C%20Shareholders%2C%20Related%20Parties%2C%20Acquirers%2C%20and%20the%20Company%20During%20and%20as%20of%20the%20End%20of%20the%20Reporting%20Period) During the reporting period, all commitment-related parties, including the company's actual controllers, shareholders, and related parties, fulfilled their share lock-up commitments made during the initial public offering or refinancing, with no overdue unfulfilled commitments as of the end of the reporting period - Share lock-up commitments by shareholders such as Alibaba Network, Founder Investment, Hainan Huayi, Tianjin Houlang, Tianjin Tongyuan, Jiaxing Chenmide, Zijin Hongyun, Suzhou Chenzhide, and Jianfa Qihao have been fulfilled, with lock-up periods of **12 or 36 months**[153](index=153&type=chunk) - Share lock-up commitments by shareholders such as CICC Qichen, CITIC Securities Investment, Jingshi Fund, HCHP, SCPE, HAL, Junlian Xinkang, and ASP have been fulfilled, with lock-up periods of **12 or 36 months**[153](index=153&type=chunk)[154](index=154&type=chunk)[155](index=155&type=chunk) - Share lock-up commitments by directors, supervisors, and senior management such as Gao Yu, Xie Wandong, Kong Xiangqian, Li Bo, Xiao Zhenrui, and Zhang Shengtang have been fulfilled, with a lock-up period of **12 months**, and they comply with share reduction regulations during and after their tenure[155](index=155&type=chunk